134 related articles for article (PubMed ID: 18452103)
1. High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study.
Lai R; Bartlett NL; Mackey JR; Jung SH; Johnson JL; Cook JR; Jones D; Cass CE; Young JD; Said J; Cheson B; Hsi ED
Leuk Lymphoma; 2008 Jun; 49(6):1202-5. PubMed ID: 18452103
[No Abstract] [Full Text] [Related]
2. hENT1 and Hodgkin lymphoma: not just crossing the channel.
Kirschbaum M
Leuk Lymphoma; 2008 Jun; 49(6):1024-5. PubMed ID: 18569632
[No Abstract] [Full Text] [Related]
3. Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma.
Sivam V; Cook L; Hughes G; Karadimitris A; Marks AJ; Matthey F; Naresh KN; Szydlo RM; Yarranton H; Kanfer EJ; Macdonald DH
Hematol Oncol; 2012 Dec; 30(4):214-5. PubMed ID: 22422565
[No Abstract] [Full Text] [Related]
4. Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children.
Jaffray M; Buchbinder N; Lutun A; Schneider P; Piquenot JM; Vannier JP
Ann Hematol; 2015 Aug; 94(8):1401-6. PubMed ID: 25862234
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
Bartlett NL; Niedzwiecki D; Johnson JL; Friedberg JW; Johnson KB; van Besien K; Zelenetz AD; Cheson BD; Canellos GP;
Ann Oncol; 2007 Jun; 18(6):1071-9. PubMed ID: 17426059
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease.
Reiman T; Clarke ML; Dabbagh L; Vsianska M; Coupland RW; Belch AR; Baldwin SA; Young JD; Cass CE; Mackey JR
Leuk Lymphoma; 2002 Jul; 43(7):1435-40. PubMed ID: 12389626
[TBL] [Abstract][Full Text] [Related]
8. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
Naqi N; Ahmad S; Shah I; Khattak J
J Coll Physicians Surg Pak; 2013 Jun; 23(6):397-400. PubMed ID: 23763798
[TBL] [Abstract][Full Text] [Related]
9. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
10. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
Blum KA; Jung SH; Johnson JL; Lin TS; Hsi ED; Lucas DM; Byrd JC; Cheson BD; Bartlett NL;
Ann Oncol; 2010 Nov; 21(11):2246-2254. PubMed ID: 20423913
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in advanced Hodgkin lymphoma.
Chen JH; Chang PY; Yao NS
Hematol Oncol Stem Cell Ther; 2009; 2(2):371-2. PubMed ID: 20118065
[No Abstract] [Full Text] [Related]
13. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
Arai S; Letsinger R; Wong RM; Johnston LJ; Laport GG; Lowsky R; Miklos DB; Shizuru JA; Weng WK; Lavori PW; Blume KG; Negrin RS; Horning SJ
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1145-54. PubMed ID: 20197102
[TBL] [Abstract][Full Text] [Related]
14. Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin's lymphoma and primary mediastinal B cell lymphoma.
Panda T; Rainchwar S; Halder R; Singh R; Bhurani D; Agrawal N
Ann Hematol; 2024 Jan; 103(1):347-349. PubMed ID: 37740065
[No Abstract] [Full Text] [Related]
15. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.
Rassidakis GZ; Medeiros LJ; Vassilakopoulos TP; Viviani S; Bonfante V; Nadali G; Herling M; Angelopoulou MK; Giardini R; Chilosi M; Kittas C; McDonnell TJ; Bonadonna G; Gianni AM; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
Blood; 2002 Dec; 100(12):3935-41. PubMed ID: 12433696
[TBL] [Abstract][Full Text] [Related]
16. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.
Michallet AS; Guillermin Y; Deau B; Lebras L; Harel S; Amorin S; Reynes C; Salles G; Subtil F; Brice P
Haematologica; 2015 Jul; 100(7):e269-71. PubMed ID: 25840598
[No Abstract] [Full Text] [Related]
17. Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study.
Xiros N; Economopoulos T; Valsami S; Rontogianni D; Fountzilas G; Raptis S
Leuk Res; 2003 Dec; 27(12):1097-9. PubMed ID: 12921946
[TBL] [Abstract][Full Text] [Related]
18. Minimal-change nephrotic syndrome preceding Hodgkin lymphoma by 5 years with expression of tumor necrosis factor alpha in Hodgkin-Reed-Sternberg cells.
Nakayama S; Yokote T; Kobayashi K; Hirata Y; Akioka T; Hiraoka N; Oka S; Miyoshi T; Takubo T; Tsuji M; Hanafusa T
Hum Pathol; 2010 Aug; 41(8):1196-9. PubMed ID: 20624522
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim.
Spencer A; Reed K; Arthur C
Intern Med J; 2007 Nov; 37(11):760-6. PubMed ID: 17542998
[TBL] [Abstract][Full Text] [Related]
20. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]